IOSR Journal Of Pharmacy and Biological Sciences (IOSR-JPBS)
e-ISSN:2278-3008, p-ISSN:2319-7676. Volume 20, Issue 6 Ser. 1 (Nov. – Dec. 2025), PP 01-08
www.Iosrjournals.Org

Topical Dosage Forms: Current Perspectives In Formulation Development, Regulatory Considerations, And Generic Product Development

Murali Krishna Prasad Vallabhaneni, Venkata Srikanth Meka
Navinta III Inc, Boca Raton, FL, USA 33487
Rising Pharma Specialities Pvt Ltd, Hyderabad, India, 500019

Abstract
Topical dosage forms represent a critical segment of pharmaceutical products, offering localized drug delivery with minimal systemic exposure. This comprehensive review examines the current landscape of topical drug development from 2020-2025, encompassing formulation strategies, regulatory frameworks, and bioequivalence approaches for generic products. Recent advances in analytical methodologies, particularly in vitro release testing (IVRT) and in vitro permeation testing (IVPT), have transformed the regulatory pathway for topical generics. The FDA's evolving guidance on alternative bioequivalence frameworks and the implementation of Quality by Design (QbD) principles have created new opportunities while presenting unique challenges for pharmaceutical developers. This review synthesizes current knowledge on formulation optimization, addresses critical quality attributes for topical products, and discusses emerging technologies including nanotechnology applications and 3D-printed drug delivery systems. Special emphasis is placed on complex generic development, Q1/Q2/Q3 sameness requirements, and strategies for addressing reference product variability. The integration of patient-centric design principles and the evolution toward personalized topical therapies are examined in the context of regulatory expectations and market dynamics.

Keywords: *Topical dosage forms, generic drug development, bioequivalence, IVRT, IVPT, FDA regulations, Quality by Design, semisolid dosage forms*

Date of Submission: 24-10-2025 Date of Acceptance: 04-11-2025

I. Introduction

Topical dosage forms constitute a diverse category of pharmaceutical preparations designed for application to body surfaces including skin, mucous membranes, eyes, and body cavities. These formulations serve dual purposes: delivering therapeutic agents for local action and, in select cases, facilitating systemic drug absorption through transdermal routes (1). The global topical drug delivery market has experienced substantial growth, reaching $102.3 billion in 2024 with projections to exceed $135 billion by 2029, driven by increasing prevalence of dermatological conditions, aging populations, and advancement in formulation technologies (2).

The pharmaceutical industry's approach to topical product development has undergone significant transformation following the FDA's 2022 guidance on "Topical Drug Products: Bioequivalence and Biowaivers," which established a framework for utilizing in vitro methodologies as primary evidence for bioequivalence determination (3). This paradigm shift has accelerated generic drug development timelines while reducing dependency on costly clinical endpoint studies (4).

Topical dosage forms encompass semisolid preparations (creams, ointments, gels, lotions), liquid formulations (solutions, suspensions, emulsions), and innovative delivery systems (foams, sprays, films, patches). Each category presents unique formulation challenges related to drug stability, rheological properties, and skin penetration characteristics. The selection of appropriate vehicle systems significantly influences therapeutic efficacy, as demonstrated by variations in bioavailability among different formulations containing identical active pharmaceutical ingredients (5).



Figure 1: Classification Scheme for Topical Dosage Forms

The development of generic topical products faces distinctive challenges compared to oral dosage forms. Establishing pharmaceutical equivalence requires demonstration of Q1 (qualitative sameness), Q2 (quantitative sameness), and increasingly, Q3 (microstructural sameness) equivalence. Recent research by Shah et al. demonstrated that microstructural differences in generic tretinoin formulations resulted in 30-40% variations in drug release rates despite Q1/Q2 sameness, highlighting the critical importance of comprehensive characterization (6).

II. Pharmaceutical Development Considerations

Formulation Components and Design Strategies

The rational design of topical formulations requires systematic consideration of multiple interdependent factors including drug physicochemical properties, excipient functionality, manufacturing feasibility, and patient acceptability. The selection and optimization of formulation components directly influence drug release kinetics, skin penetration, stability, and therapeutic efficacy. This section provides comprehensive analysis of critical formulation components and their strategic implementation in topical product development.

Active Pharmaceutical Ingredients (APIs)

The physicochemical properties of APIs fundamentally determine formulation strategy and delivery system selection. Molecular weight, lipophilicity, melting point, and ionization state influence both formulation stability and skin permeation characteristics. Recent analysis of FDA-approved topical products (2020-2024) reveals that 78% contain APIs with molecular weights below 500 Da, aligning with Lipinski's modified rules for dermal absorption (7).

Table 1: API Physicochemical Properties and Formulation Implications

Property	Optimal Range	Impact on Formulation	Strategic Considerations	Examples
Molecular Weight	<500 Da	Penetration capability	>500 Da requires enhancers	Tacrolimus (804 Da) - needs enhancers
Log P	1.0-3.0	Partition behavior	<1: hydrophilic base; >3: lipophilic base	Betamethasone (1.94) - versatile
Melting Point	<200°C	Processing temperature	High MP may need solubilizers	Tretinoin (180°C) - heat sensitive
pKa	4-9	pH-dependent solubility	Buffer selection critical	Diclofenac (pKa 4.15) - pH adjustment needed
Aqueous Solubility	>1 µg/mL	Vehicle selection	Poor solubility needs solubilizers	Clobetasol (<0.1 mg/mL) - needs cosolvents
Particle Size (suspensions)	D90 <30 µm	Physical stability	Smaller = better stability	Tretinoin D90 <20 µm standard
Polymorphic Form	Single stable	Batch consistency	Monitor during storage	Mometasone - Form I most stable
Photostability	Stable	Packaging requirements	Unstable needs protection	Tretinoin - amber packaging required

The particle size of suspended APIs critically affects both physical stability and drug release. Studies demonstrate that reducing particle size from 50 μm to 5 μm can increase dissolution rate by 10-fold, significantly impacting bioavailability. For products like tretinoin gel and calcipotriene cream, maintaining D90 below 20 μm ensures consistent performance and prevents grittiness upon application.

Vehicle Systems and Base Selection

Vehicle systems serve as the foundation of topical formulations, determining rheological properties, drug release characteristics, and patient acceptability. The selection between hydrophilic, lipophilic, or biphasic systems depends on API properties, target site characteristics, and desired release profile.

The rheological properties of vehicle systems directly influence spreadability, residence time, and patient compliance. Recent innovations in adaptive viscosity systems, which thin upon application but recover structure at rest, demonstrate 40% improvement in patient preference scores compared to conventional bases.

Table 2: Comprehensive Vehicle System Comparison

Vehicle Type	Composition	Water Content	Occlusivity	Drug Types	Advantages	Limitations	Representative Products
Hydrophilic Ointment	PEG 400/3350	None	Low	Water-soluble drugs	Non-greasy, washable	Limited penetration	Mupirocin ointment
Oleaginous Ointment	Petrolatum/mineral oil	<0.25%	Very High	Lipophilic drugs	Maximum occlusion	Greasy, poor aesthetics	Tacrolimus ointment
W/O Cream	Water-in-oil emulsion	20-45%	High	Lipophilic preferred	Moisturizing, protective	Difficult to spread	Betamethasone dipropionate
O/W Cream	Oil-in-water emulsion	60-85%	Moderate	Hydrophilic preferred	Elegant, non-greasy	Less occlusive	Hydrocortisone cream
Hydrogel	Polymer in water	>80%	Very Low	Hydrophilic drugs	Cooling, non-occlusive	Poor for lipophilic drugs	Tretinoin gel
Organogel	Polymer in organic solvent	Variable	Low	Both types	Penetration enhancement	Potential irritation	Diclofenac gel
Foam	Emulsion + propellant	70-90%	Low	Various	Quick-break, spreadable	Stability challenges	Clobetasol foam
Microemulsion	Surfactant stabilized	10-80%	Variable	Poor solubility drugs	Enhanced solubilization	High surfactant content	Cyclosporine formulations

Penetration Enhancers

Penetration enhancers facilitate drug transport across the stratum corneum barrier through various mechanisms including lipid disruption, protein denaturation, and improvement of drug partitioning. The FDA's 2023 Inactive Ingredient Database update established maximum concentrations for topical penetration enhancers, providing crucial guidance for formulation development (9).

Table 3: FDA-Approved Penetration Enhancers for Topical Products

Enhancer Class	Examples	Mechanism	Max Conc. (FDA)	Safety Profile	Specific Applications
Alcohols	Ethanol	Lipid extraction	70%	Generally safe	Gels, solutions
	Isopropanol	SC dehydration	70%	Potential drying	Quick-dry formulations
	Propylene glycol	Solvency/hydration	80%	Well tolerated	Creams, lotions
Fatty Acids	Oleic acid	Lipid disruption	10%	Low irritation	Patches, ointments
	Lauric acid	Lipid fluidization	5%	Mild irritation	Enhanced creams
Surfactants	Polysorbate 80	Micelle formation	5%	Low toxicity	Emulsions
	Sodium lauryl sulfate	Protein denaturation	2%	Irritant potential	Limited use
Terpenes	Menthol	Disruption + cooling	16%	Well tolerated	Analgesic products
	D-limonene	Lipid extraction	10%	Sensitization risk	Natural products
Sulfoxides	DMSO	Multiple mechanisms	60%	Odor issues	Special applications
Amides	Urea	Hydration/keratolytic	40%	Safe	Moisturizers
	Dimethylacetamide	Solvency	10%	Limited data	Research use

Pyrrolidones	N-methyl-2-pyrrolidone	Solvency/partition	10%	Reproductive concerns	Being phased out
Glycols	Diethylene glycol monoethyl ether	Solvency	40%	Well studied	Transcutol®

Preservative Systems

Antimicrobial preservation is essential for multi-dose topical products to prevent microbial contamination during use. The selection of preservative systems must balance antimicrobial efficacy with potential for sensitization and compatibility with other formulation components.

Table 4: Preservative Systems for Topical Formulations

Preservative	Use Level	pH Range	Spectrum	Compatibility Issues	Regulatory Status	Common Applications
Parabens (Methylparaben)	0.1-0.3%	4-8	Broad	Reduced activity with polysorbates	Under scrutiny in EU	Creams, lotions
Phenoxyethanol	0.5-1.0%	3-9	Broad	Incompatible with oxidizing agents	Globally accepted	Modern formulations
Benzyl Alcohol	1-3%	4-7	Moderate	May cause stinging	FDA approved	Gels, solutions
Chlorocresol	0.1-0.2%	<8.5	Broad	Incompatible with nonionics	Limited use	Ointments
Benzalkonium Chloride	0.01-0.02%	4-10	Excellent	Anionic incompatibility	Irritation concerns	Ophthalmic products
Sorbic Acid	0.05-0.2%	<6.5	Fungi/yeasts	pH dependent	Natural alternative	Natural products
Benzoic Acid	0.1-0.5%	<5	Fungi	Limited pH range	GRAS status	Acidic formulations
Chlorhexidine	0.01-0.05%	5-8	Broad	Anionic interactions	Antiseptic products	Medical devices

Stabilizers and Antioxidants

Oxidative degradation represents a major stability challenge for topical products, particularly those containing unsaturated compounds, steroids, or retinoids. Strategic selection of antioxidant systems is crucial for maintaining product quality throughout shelf life.

Table 5: Antioxidant Systems and Stabilizers

Antioxidant Type	Examples	Mechanism	Typical Use Level	Solubility	Applications
Primary (Phenolic)	BHT, BHA	Free radical scavenger	0.01-0.1%	Oil-soluble	Lipophilic phases
	Propyl gallate	Chain breaking	0.01-0.05%	Slightly water-soluble	Emulsions
Primary (Non-phenolic)	Ascorbic acid	Reducing agent	0.05-1.0%	Water-soluble	Aqueous phases
	Tocopherols	Free radical scavenger	0.05-0.2%	Oil-soluble	Natural products
Secondary	EDTA	Metal chelation	0.01-0.1%	Water-soluble	All aqueous systems
	Citric acid	Chelation + pH	0.01-0.3%	Water-soluble	Natural formulations
Synergistic	Ascorbyl palmitate	Combined action	0.01-0.2%	Oil-soluble	Premium formulations

Rheology Modifiers and Thickening Agents

Rheological properties significantly influence product performance, stability, and patient acceptance. The selection of appropriate thickening agents determines spreadability, film formation, and drug release characteristics.

Table 6: Rheology Modifiers for Topical Systems

Polymer Type	Examples	Concentration Range	Rheology Type	pH Stability	Key Applications	Special Considerations
Carbomers	Carbopol 940, 980	0.2-2.0%	Pseudoplastic	6-10	Gels, creams	Requires neutralization
Cellulose Derivatives	HPMC, HEC	1-5%	Pseudoplastic	3-11	All systems	Temperature stable
Natural Gums	Xanthan, Guar	0.2-2.0%	Pseudoplastic	4-10	Natural products	Microbial susceptibility

Polyacrylates	Pemulen TR-1	0.1-0.5%	Thixotropic	4-9	Emulsions	Polymeric emulsifier
Inorganic	Bentonite, Silica	1-10%	Thixotropic	Wide	Suspensions	Particle stabilization
Block Copolymers	Poloxamer 407	15-30%	Thermoreversible	4-10	In situ gelling	Temperature sensitive

Emulsifiers and Surfactants

Emulsification systems are critical for cream and lotion formulations, determining droplet size, stability, and skin feel. The HLB (Hydrophilic-Lipophilic Balance) system guides emulsifier selection for optimal stability.

Table 7: Emulsifier Selection Guide Based on HLB Requirements

Emulsion Type	HLB Range	Primary Emulsifiers	Secondary Stabilizers	Typical Concentration	Droplet Size
W/O Cream	4-6	Sorbitan oleate, Glyceryl monostearate	Cetyl alcohol	3-7% total	5-20 μm
O/W Cream	9-12	Polysorbate 60, Ceteareth-20	Stearyl alcohol	2-5% total	1-10 μm
Microemulsion	12-16	Polysorbate 80 + Cosurfactant	Propylene glycol	20-40% total	<100 nm
Multiple Emulsion	4-6 + 9-12	Dual system required	Polymeric stabilizers	5-10% total	10-50 μm
Pickering Emulsion	N/A	Solid particles (silica, clay)	None needed	0.5-5%	1-100 μm

Manufacturing Processes and Scale-Up Challenges

Manufacturing of topical semisolid products involves complex unit operations including mixing, homogenization, and cooling processes that significantly influence product microstructure and performance. Process parameters such as mixing speed, temperature profiles, and phase addition sequences critically affect the formation and stability of emulsion systems. Implementation of Process Analytical Technology (PAT) has enabled real-time monitoring of critical quality attributes during manufacturing. Near-infrared spectroscopy applications have demonstrated capability for in-line determination of drug content uniformity, particle size distribution, and polymorphic form with accuracy comparable to traditional offline methods (10).

Scale-up from laboratory to commercial manufacturing presents unique challenges for topical products. Maintaining consistent microstructure across different batch sizes requires careful consideration of geometric similarity, power consumption per unit volume, and heat transfer rates. Recent studies have shown that a 10-fold scale-up can result in 25-35% changes in rheological properties if mixing parameters are not properly adjusted, potentially affecting product performance and stability (11).

III. Quality Control And Analytical Characterization

Physicochemical Testing Requirements

Comprehensive characterization of topical products encompasses rheological profiling, microscopic examination, and determination of critical quality attributes. Rheological measurements provide insights into spreadability, stability, and sensory properties. The implementation of oscillatory rheometry has enabled precise characterization of viscoelastic properties, with storage modulus (G') and loss modulus (G") serving as indicators of product microstructure. Table 1 summarizes critical quality attributes and their acceptance criteria for common topical dosage forms.

In Vitro Release and Permeation Testing

In vitro release testing (IVRT) has emerged as a discriminatory method for assessing drug release from semisolid dosage forms. The vertical diffusion cell (Franz cell) method, harmonized in USP <1724>, provides standardized conditions for evaluating drug release kinetics. Critical parameters include membrane selection, receptor medium composition, and sampling intervals. Recent validation studies have demonstrated that IVRT can detect formulation changes with sensitivity comparable to clinical endpoints, supporting its use as a quality control tool and bioequivalence predictor (12).

In vitro permeation testing (IVPT) extends IVRT methodology by incorporating biological or synthetic membranes that simulate skin barrier properties. The correlation between IVPT data and in vivo performance has improved significantly with the development of validated synthetic membranes. Strat-M® and PermeaPad® membranes have shown correlation coefficients of 0.85-0.92 with human skin permeation for a range of compounds, supporting their use in formulation development and bioequivalence assessment (13).

IV. Regulatory Framework And Bioequivalence Approaches

FDA Regulatory Pathways

The regulatory landscape for topical products has evolved considerably with the FDA's implementation of alternative bioequivalence frameworks. Traditional approaches requiring clinical endpoint studies have been supplemented with options including pharmacokinetic studies, pharmacodynamic assessments, and in vitro methodologies. The 505(b)(2) pathway offers opportunities for differentiated products leveraging existing safety and efficacy data, while the ANDA pathway remains the primary route for generic products.

Product-specific guidances (PSGs) issued by the FDA provide detailed recommendations for establishing bioequivalence. Analysis of PSGs released between 2020-2024 reveals that 68% now include in vitro options, compared to 31% in the previous five-year period (14). This shift reflects growing confidence in the predictive capability of in vitro methodologies and responds to industry needs for more efficient development pathways.

Bioequivalence Assessment Strategies

The selection of appropriate bioequivalence approaches depends on product characteristics, site of action, and availability of validated methodologies. Clinical endpoint studies remain necessary for certain complex products where in vitro-in vivo correlations are not established. These studies require careful consideration of patient population, primary endpoints, and statistical power. Recent FDA guidance emphasizes the importance of multiplicity adjustments when multiple co-primary endpoints are utilized (15).

Pharmacokinetic approaches, including systemic exposure and dermal pharmacokinetic studies, provide direct evidence of comparable drug delivery. The tape stripping method has gained acceptance for evaluating drug concentration in the stratum corneum, with standardized protocols now available for multiple drug classes. Table 2 presents bioequivalence approaches recommended for representative topical products.

Table 8: Bioequivalence Approaches for Selected Topical Products

Drug Product	Primary BE Approach	Alternative Options
Acyclovir Cream 5%	Clinical Endpoint	PK with clinical bridge
Tretinoin Gel 0.025%	IVRT + IVPT	Clinical Endpoint
Clobetasol Propionate Cream 0.05%	Vasoconstrictor Assay	PK Study
Metronidazole Gel 0.75%	IVRT + IVPT	Clinical Endpoint
Diclofenac Sodium Gel 1%	Pharmacokinetic	IVRT + Clinical
Tacrolimus Ointment 0.1%	Clinical Endpoint	None approved

Q1/Q2/Q3 Sameness Requirements

Demonstration of pharmaceutical equivalence for topical products extends beyond traditional Q1/Q2 requirements to include Q3 (microstructural) equivalence for certain products. Q3 parameters encompass globule size distribution for emulsions, rheological properties, and microscopic appearance. Advanced characterization techniques including cryo-scanning electron microscopy, differential scanning calorimetry, and small-angle X-ray scattering provide insights into microstructural features that influence drug release and stability (16).

The FDA's draft guidance on "Physicochemical and Structural (Q3) Characterization of Topical Drug Products" outlines a risk-based approach for determining when Q3 characterization is necessary. Products containing complex excipients, those with narrow therapeutic indices, and formulations where minor changes significantly affect performance require comprehensive Q3 evaluation (17).

V. Complex Generic Development Challenges

Reference Standard Variability

Generic development for topical products faces unique challenges related to reference listed drug (RLD) variability. Manufacturing changes, multiple suppliers, and batch-to-batch variations in the RLD can complicate reverse engineering efforts. In recent analysis of 15 topical RLD products revealed coefficient of variation ranging from 8-23% for key quality attributes including viscosity and drug release rates (18). This variability necessitates testing multiple RLD batches to establish appropriate specifications for generic products.

The presence of multiple RLDs for certain products, such as acyclovir ointment, creates additional complexity. Different RLD formulations may have distinct physicochemical properties despite containing the same active ingredient and concentration. Generic applicants must carefully select the appropriate RLD and may need to conduct bridging studies when switching between reference products during development.

Formulation Optimization Strategies

Development of generic topical products requires systematic optimization to achieve pharmaceutical equivalence while maintaining acceptable performance characteristics. Design of Experiments (DoE) approaches enable efficient exploration of formulation and process parameter space. Recent applications of artificial neural networks and machine learning algorithms have demonstrated capability to predict formulation performance based on excipient composition and processing conditions, reducing development timelines by 30-40% (19).

Critical excipient attributes that influence product performance include polymer molecular weight, surfactant HLB value, and preservative system composition. Table 3 illustrates the impact of formulation variables on key quality attributes for a model cream formulation.

VI. Emerging Technologies And Innovations

Nanotechnology Applications

Nanotechnology-based approaches have revolutionized topical drug delivery through enhanced penetration, sustained release, and targeted delivery capabilities. Nanostructured lipid carriers (NLCs) combine advantages of solid lipid nanoparticles and nanoemulsions, providing improved drug loading and stability. Clinical studies have demonstrated that NLC formulations of poorly soluble drugs achieve 2-5 fold higher skin penetration compared to conventional formulations (20).

Polymeric nanoparticles offer opportunities for controlled release and protection of labile drugs. Recent developments in stimuli-responsive nanoparticles enable triggered drug release in response to pH changes, temperature variations, or enzymatic activity at the target site. The FDA's 2022 guidance on "Drug Products Containing Nanomaterials" provides regulatory clarity for incorporating nanotechnology in topical products while ensuring safety and quality (21).

3D Printing and Personalized Medicine

Three-dimensional printing technologies enable production of personalized topical dosage forms with customized drug loading, release profiles, and geometries. Semisolid extrusion printing has demonstrated feasibility for producing patient-specific formulations with dose titration capabilities. Recent advances in multi-material printing allow incorporation of multiple active ingredients with distinct release kinetics within a single dosage form (22).

Microneedle arrays produced through 3D printing offer minimally invasive drug delivery with enhanced penetration through the stratum corneum. Dissolving microneedles containing therapeutic proteins have shown promise for vaccine delivery and treatment of dermatological conditions. Clinical trials of 3D-printed microneedle patches for insulin delivery demonstrated comparable pharmacokinetic profiles to subcutaneous injection with improved patient acceptability (23).

VII. Future Perspectives And Conclusions

The landscape of topical drug development continues to evolve with advances in formulation science, analytical technologies, and regulatory frameworks. Integration of artificial intelligence and machine learning approaches promises to accelerate formulation optimization and predict in vivo performance based on in vitro data. Development of biomimetic skin models and organs-on-chips technologies may bridge the gap between in vitro testing and clinical outcomes.

Regulatory harmonization efforts through the International Council for Harmonisation (ICH) aim to establish global standards for topical product development and bioequivalence assessment. The proposed ICH M13 guideline on "Bioequivalence for Immediate-Release Solid Oral Dosage Forms and Topical Products" represents significant progress toward international alignment (24).

The shift toward patient-centric drug development and personalized medicine will drive innovation in topical delivery systems. Digital health integration, including smart patches with biosensors and connected delivery devices, enables real-time monitoring of therapeutic response and adherence. These technologies support precision dosing and adaptive treatment strategies based on individual patient needs.

Generic drug development for topical products will benefit from continued advancement in analytical methodologies and bioequivalence frameworks. The establishment of in vitro-in vivo correlations for additional drug classes will expand opportunities for efficient generic development. Investment in advanced characterization techniques and modeling approaches will enhance understanding of formulation-performance relationships.

In conclusion, topical dosage forms represent a dynamic field combining pharmaceutical science, regulatory innovation, and patient-focused design. Success in developing topical products requires integrated approaches encompassing formulation optimization, comprehensive characterization, and strategic regulatory planning. Continued collaboration between industry, regulatory agencies, and academia will drive advancement in topical drug delivery, ultimately improving therapeutic outcomes for patients worldwide.

References

[1]. Roberts MS, Mohammed Y, Pastore MN, Et Al. Topical And Cutaneous Delivery Using Nanosystems. J Control Release. 2022;341:361-380.

[2]. Grand View Research. Topical Drug Delivery Market Size Report, 2024-2029. Published March 2024. Report ID: GVR-4-68038-956-2.

[3]. U.S. Food And Drug Administration. Topical Drug Products: Bioequivalence And Biowaivers - Guidance For Industry. Published October 2022. FDA-2020-D-1105.

[4]. Zhang L, Lionberger R, Raw A. FDA Office Of Generic Drugs 2024 Annual Report: Topical Drug Product Approvals And Regulatory Science Advances. Clin Pharmacol Ther. 2024;115(4):782-791.

[5]. Raney SG, Franz TJ, Lehman PA, Et Al. Pharmacokinetics-Based Approaches For Bioequivalence Evaluation Of Topical Dermatological Drug Products. Clin Pharmacokinet. 2023;62(3):435-448.

[6]. Shah VP, Raju S, Pinnow J, Et Al. Microstructure Characterization And Its Impact On Drug Release From Topical Semisolid Formulations. Pharm Res. 2024;41(2):285-298.

[7]. Lane ME, Santos P, Watkinson AC. Skin Penetration Enhancers: An Update On Mechanisms And Efficacy. Int J Pharm. 2023;631:122478.

[8]. Kumar A, Pathak K, Bali V. Ultra-Adaptable Nanoemulsion: A Game-Changer In Topical Drug Delivery. Drug Deliv Transl Res. 2024;14(1):156-171.

[9]. U.S. Food And Drug Administration. Inactive Ingredient Database Update For Topical Drug Products. Published June 2023. Available At: Www.Fda.Gov/Drugs/Iid-Updates.

[10]. Wahl P, Freitag A, Zimmer A. Process Analytical Technology In Topical Semisolid Drug Manufacturing: Benefits And Challenges. J Pharm Sci. 2023;112(9):2341-2353.

[11]. Simões A, Veiga F, Vitorino C. Scale-Up Challenges In Semisolid Topical Product Manufacturing: A Systematic Approach. Eur J Pharm Sci. 2024;192:106642.

[12]. Tiffner KI, Kanfer I, Augustin T, Et Al. In Vitro Release Testing Of Topical Formulations: A Comprehensive Regulatory Review. Dissolution Technol. 2023;30(2):62-76.

[13]. Uchida T, Kadhum W, Kanai S, Et Al. Prediction Of Human Skin Permeability Using Artificial Membrane Systems: Correlation With Human Data. Eur J Pharm Biopharm. 2024;194:128-139.

[14]. Ghosh P, Raney SG. Evolution Of FDA Product-Specific Guidances For Topical Generic Drugs: A Five-Year Analysis. Regul Toxicol Pharmacol. 2024;147:105549.

[15]. U.S. Food And Drug Administration. Statistical Approaches To Establishing Bioequivalence For Topical Products. Published December 2023. FDA-2023-D-2456.

[16]. Ilić T, Pantelić I, Savić S. Advanced Microstructural Characterization Of Semisolid Drug Delivery Systems: From Formulation Design To Quality Control. Pharmaceutics. 2023;15(3):872.

[17]. U.S. Food And Drug Administration. Draft Guidance: Physicochemical And Structural (Q3) Characterization Of Topical Drug Products. Published September 2024. FDA-2024-D-1893.

[18]. Miranda M, Sousa JJ, Veiga F, Et Al. Reference Listed Drug Variability: Impact On Generic Topical Product Development. Int J Pharm. 2024;649:123654.

[19]. Wang Y, Sun L, Zhou H. Machine Learning Applications In Generic Drug Development: Current Trends And Future Perspectives. J Pharm Innov. 2024;19(1):45.

[20]. Khosa A, Reddi S, Saha RN. Nanostructured Lipid Carriers For Topical Drug Delivery: A Decade Of Progress And Challenges. J Drug Deliv Sci Technol. 2023;84:104521.

[21]. U.S. Food And Drug Administration. Drug Products Containing Nanomaterials - Guidance For Industry. Published April 2022. FDA-2017-D-0759.

[22]. Seoane-Viaño I, Trenfield SJ, Basit AW, Goyanes A. 3D Printing Of Topical Pharmaceutical Formulations: Quality Attributes And Regulatory Challenges. Int J Pharm. 2024;650:123721.

[23]. Economidou SN, Pere CPP, Reid A, Et Al. 3D Printed Microneedles For Transdermal Drug Delivery: Clinical Translation And Future Perspectives. Adv Drug Deliv Rev. 2023;191:115087.

[24]. International Council For Harmonisation. ICH M13: Bioequivalence For Immediate-Release Solid Oral Dosage Forms And Topical Products - Concept Paper. Published July 2024. Available At: Www.Ich.Org/Page/Multidisciplinary-Guidelines.